Johnson & Johnson Announces Departure of China VP and Chief Digital Officer Dai Ying Amid Strategic Leadership Transition

It is reported that Joanna Wan, head of Johnson & Johnson's R&D team in China, has temporarily taken on the leadership of the company's digital team in China.

Dai Ying's career is nothing short of legendary. He joined GE Healthcare in 1998 and served for 24 years, holding positions such as Manager of the China Region and the U.S. Engineering Department, as well as Global Supply Chain Production Operations Manager.

Since 2010, he has been appointed as the Chief Technology Officer of GE Healthcare China, Chief Marketing Officer, General Manager of GE China's Global Research and Development Center, and Vice President and Chief Innovation Officer of GE Healthcare China.

During his tenure at GE Healthcare, Dai Ying formulated the localization strategy for GE Healthcare China, established a digital business framework, and promoted the largest number of localization projects in GE China's history as well as its largest-scale digital transformation.

In April 2022, Dai Ying joined Johnson & Johnson Medical (China) Ltd., serving as Vice President and Chief Digital Officer. During his more than three years at Johnson & Johnson, he led the formulation of a digital innovation strategy, developed digital infrastructure and solutions, and drove the digital transformation of Johnson & Johnson Medical’s business in China.

Johnson & Johnson China Reports Strong Q1 2025 Performance. Revenue from Johnson & Johnson’s MedTech business in China reached $8 billion, a year-over-year increase of 2.5%. Notably, the cardiovascular segment performed exceptionally well, with sales reaching $2.1 billion, marking a 16.5% year-over-year growth and serving as the primary growth driver.

Moreover, Johnson & Johnson has made progress in innovative products, such as the completion of the first clinical trials for the Ottava™ robotic surgical system. Despite a low single-digit decline in the peripheral vascular business due to the volume-based procurement policy in China, the overall business remains robust.

Notably, in April 2024, Will Song (Song Weiqun), Chairman of Johnson & Johnson's China Region and President of Johnson & Johnson Medical Technology China, submitted his resignation to pursue external development opportunities. Song Weiqun had been with Johnson & Johnson for over 20 years, joining in 2003, becoming President of Johnson & Johnson Medical Technology China in 2015, and serving as Chairman of Johnson & Johnson’s China Region since 2018. Song Weiqun’s departure marks the end of a significant era for Johnson & Johnson in China.

After Song Weiqun's departure, he joined GE Healthcare on April 1, 2025, taking over the position of President and CEO of GE Healthcare China from Zhang Yihao. Zhang Yihao will officially retire on July 1, 2025. Since joining GE Healthcare in 2019, Zhang Yihao has been fully responsible for the company’s strategic development and operations in China, driving long-term growth in the market.